Remdesivir: An Emergency Solution for the Treatment of Mild/Moderate and Severe COVID-19 Hospitalized Patients
International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
www.ijsr.net | Open Access | Fully Refereed | Peer Reviewed International Journal

ISSN: 2319-7064

Review Papers | Medicine | United States of America | Volume 9 Issue 10, October 2020

Remdesivir: An Emergency Solution for the Treatment of Mild/Moderate and Severe COVID-19 Hospitalized Patients

Elizabeth Z Zakka

Novel Coronavirus Disease (COVID-19) is caused by a zoonotic virus that belongs to the coronavirus family with a close relationship with the bat-SARS-like coronavirus strain BatCov RaTG13. Up until this day, no treatment option has been found to be completely effective against this virus clinically and theoretically. Veclury (remdesivir) is an RNA polymerase antiviral made by Gilead Sciences, Inc. and it has shown some promising results for patients hospitalized due to COVID-19 with mild/moderate and severe disease. According to this, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for healthcare providers permitting the emergency use of remdesivir for the treatment of COVID-19 hospitalized patients. The FDA based its EUA on data collected from clinical trials that used remdesivir. Examples of these trials are National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trial (ACTT-1) Trial in Subjects with Mild/Moderate and Severe Covid-19, Study GS-US-540-5773; Remdesivir for 5 or 10 Days in Patients with Severe Covid-19; a randomized, open label, multi-center clinical trial, and Study GS-US-540-5774; Effect of Remdesivir vs. Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19, A Randomized Clinical Trial. According to these trials, and others as well, remdesivir could be used as an intravenous infusion for 5 to 10 days depending on the severity of the disease.

Keywords: COVID-19, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, Remdesivir, Veclury

Edition: Volume 9 Issue 10, October 2020

Pages: 1016 - 1020

Share this Article

How to Cite this Article?

Elizabeth Z Zakka, "Remdesivir: An Emergency Solution for the Treatment of Mild/Moderate and Severe COVID-19 Hospitalized Patients", International Journal of Science and Research (IJSR), https://www.ijsr.net/search_index_results_paperid.php?id=SR201014194615, Volume 9 Issue 10, October 2020, 1016 - 1020

63 PDF Views | 30 PDF Downloads

Download Article PDF



Similar Articles with Keyword 'COVID-19'

Case Studies, Medicine, India, Volume 9 Issue 11, November 2020

Pages: 697 - 700

Treatment Strategies in Clinically and Radiologically Suspicious but RTPCR Negative Cases of COVID-19 (Case Report)

Dr. Saurabh Tyagi, Dr. Frank P, Dr. Trinath Dash

Share this Article

Research Paper, Medicine, India, Volume 9 Issue 11, November 2020

Pages: 909 - 914

Clinical Profile of COVID-19 Patients and QT Interval Changes with Drugs used for Empirical Treatment: A Case Series from Eastern India

Dr. Pradip Saha, Dr Avijit Hazra

Share this Article

Review Papers, Medicine, India, Volume 9 Issue 9, September 2020

Pages: 1132 - 1135

Interleukin 6: The Best Marker for COVID-19 Disease Severity

Gagandeep Malik

Share this Article

Review Papers, Medicine, United States of America, Volume 9 Issue 10, October 2020

Pages: 1016 - 1020

Remdesivir: An Emergency Solution for the Treatment of Mild/Moderate and Severe COVID-19 Hospitalized Patients

Elizabeth Z Zakka

Share this Article

Review Papers, Medicine, Indonesia, Volume 9 Issue 8, August 2020

Pages: 960 - 965

Management of Urinary Incontinence and Alvi Incontinence in the COVID-19 Pandemic Era

I Gde Sastra Winata, I Putu Rian Cipta Pramana Putra

Share this Article

Similar Articles with Keyword 'SARS-CoV-2'

Research Paper, Medicine, India, Volume 9 Issue 11, November 2020

Pages: 909 - 914

Clinical Profile of COVID-19 Patients and QT Interval Changes with Drugs used for Empirical Treatment: A Case Series from Eastern India

Dr. Pradip Saha, Dr Avijit Hazra

Share this Article

Review Papers, Medicine, United States of America, Volume 9 Issue 10, October 2020

Pages: 1016 - 1020

Remdesivir: An Emergency Solution for the Treatment of Mild/Moderate and Severe COVID-19 Hospitalized Patients

Elizabeth Z Zakka

Share this Article

Review Papers, Medicine, India, Volume 9 Issue 11, November 2020

Pages: 45 - 51

COVID-19 Vaccination Strategies and Challenges - A Literature Review

Dr Vidit Majmundar, Dr Purva Shah

Share this Article

Informative Article, Medicine, India, Volume 9 Issue 6, June 2020

Pages: 69 - 73

Use of Mefenamic Acid as a Supportive Treatment of COVID-19: A Repurposing Drug

Dr. R. P. Pareek

Share this Article

Similar Articles with Keyword 'severe acute respiratory syndrome coronavirus 2'

Review Papers, Medicine, United States of America, Volume 9 Issue 10, October 2020

Pages: 1016 - 1020

Remdesivir: An Emergency Solution for the Treatment of Mild/Moderate and Severe COVID-19 Hospitalized Patients

Elizabeth Z Zakka

Share this Article

Informative Article, Medicine, India, Volume 9 Issue 6, June 2020

Pages: 69 - 73

Use of Mefenamic Acid as a Supportive Treatment of COVID-19: A Repurposing Drug

Dr. R. P. Pareek

Share this Article
Top